- Trials with a EudraCT protocol (28,934)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
28,934 result(s) found for: Informed Consent.
Displaying page 1 of 1,447.
EudraCT Number: 2018-002747-29 | Sponsor Protocol Number: BIA-2093-213 | Start Date*: 2019-04-24 | |||||||||||
Sponsor Name:Bial - Portela & Ca, S.A. | |||||||||||||
Full Title: Prevention of epilepsy in stroke patients at high risk of developing unprovoked seizures: anti-epileptogenic effects of eslicarbazepine acetate | |||||||||||||
Medical condition: Adult patients at high-risk to develop post-stroke epilepsy | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Completed) SE (Completed) GB (GB - no longer in EU/EEA) PT (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2018-000175-33 | Sponsor Protocol Number: D9484C00001 | Start Date*: 2018-06-21 | |||||||||||
Sponsor Name:AstraZeneca AB | |||||||||||||
Full Title: A Phase II, Randomised, Double-Blind, Placebo Controlled, Parallel-Group, Multicentre, Three Month Duration Potassium Reduction Initiative to Optimize RAAS Inhibition Therapy with Sodium Zirconium ... | |||||||||||||
Medical condition: Heart Failure; Hyperkalaemia | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: HU (Prematurely Ended) SK (Prematurely Ended) PL (Prematurely Ended) BG (Prematurely Ended) RO (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2018-002620-17 | Sponsor Protocol Number: 18-513 | Start Date*: 2019-01-08 | |||||||||||
Sponsor Name:Portola Pharmaceuticals, Inc | |||||||||||||
Full Title: A PHASE 4 RANDOMIZED CLINICAL TRIAL OF ANDEXANET ALFA [ANDEXANET ALFA FOR INJECTION] IN ACUTE INTRACRANIAL HEMORRHAGE IN PATIENTS RECEIVING AN ORAL FACTOR XA INHIBITOR | |||||||||||||
Medical condition: Oral FXa inhibitor-treated patients with acute intracranial bleeding. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) DE (Completed) GB (GB - no longer in EU/EEA) AT (Completed) BE (Completed) NL (Completed) ES (Prematurely Ended) GR (Completed) CZ (Completed) LV (Completed) FI (Prematurely Ended) NO (Prematurely Ended) LT (Prematurely Ended) PL (Completed) PT (Prematurely Ended) DK (Prematurely Ended) IT (Prematurely Ended) HU (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2004-000913-21 | Sponsor Protocol Number: D1444C00147 | Start Date*: 2004-10-05 |
Sponsor Name:AstraZeneca R&D Södertälje | ||
Full Title: A 12-week International, Multicenter, Open Label, Non-comparative Study to Evaluate the Feasibility of Switching any Antipsychotic Treatment to Sustained-release Quetiapine Fumarate (SEROQUEL) in P... | ||
Medical condition: Schizophrenia | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: FI (Completed) HU (Completed) LV (Completed) EE (Completed) | ||
Trial results: View results |
EudraCT Number: 2008-000369-44 | Sponsor Protocol Number: 111375 | Start Date*: 2009-03-24 |
Sponsor Name:GlaxoSmithKline Biologicals | ||
Full Title: A long-term, open follow-up of the immunogenicity and safety of GlaxoSmithKline Biologicals’ HPV-16/18 VLP/AS04 vaccine in healthy female subjects up to 10 years after administration of the first v... | ||
Medical condition: For the prevention of high-grade cervical intraepithelial neoplasia (CIN grades 2 and 3) and cervical cancer causally related to human papillomavirus (HPV) types 16 and 18. | ||
Disease: | ||
Population Age: Adolescents, Under 18, Adults | Gender: Female | |
Trial protocol: DE (Completed) | ||
Trial results: View results |
EudraCT Number: 2008-003597-18 | Sponsor Protocol Number: 18F-AV-45-010 | Start Date*: 2009-05-28 | |||||||||||
Sponsor Name:Avid Radiopharmaceuticals, Inc | |||||||||||||
Full Title: A study evaluating the imaging characteristics of 18F-AV-45 in patients with frontotemporal dementia compared to patients with Alzheimer's disease and normal controls | |||||||||||||
Medical condition: Use of 18F-AV-45 positron emission tomography as early diagnostic technique in frontal lobe dementia and Alzheimer's disease. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2021-000399-12 | Sponsor Protocol Number: GPHIP_0202 | Start Date*: 2021-04-16 | |||||||||||
Sponsor Name:Grand Medical Pty Ltd | |||||||||||||
Full Title: A Randomized, Open-Label, Multi-Centre, Phase 2a Study to Evaluate the Safety and Effect of STC3141 Continuous Infusion in Subjects with Severe COVID-19 Pneumonia | |||||||||||||
Medical condition: severe pneumonia due to COVID-19 | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) PL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2023-000765-14 | Sponsor Protocol Number: 217270 | Start Date*: 2023-10-03 |
Sponsor Name:GlaxoSmithKline Biologicals SA | ||
Full Title: A prospective, multi-center post marketing surveillance (PMS) study to monitor the safety of GlaxoSmithKline Biologicals’ SA’s (GSK) Meningococcal Group B (Bexsero) vaccine in Korean participants, ... | ||
Medical condition: The study will collect real-world post-vaccination adverse events. | ||
Disease: | ||
Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | |
Trial protocol: Outside EU/EEA | ||
Trial results: (No results available) |
EudraCT Number: 2014-004049-29 | Sponsor Protocol Number: ISSBRIL0264 | Start Date*: 2015-03-10 |
Sponsor Name:University of Leicester | ||
Full Title: Investigating Aspirin and Ticagrelor for the prevention of tumour cell-induced platelet aggregation | ||
Medical condition: Solid cancer metastasis | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (Completed) | ||
Trial results: View results |
EudraCT Number: 2021-002011-61 | Sponsor Protocol Number: 77267 | Start Date*: 2021-08-13 |
Sponsor Name:Academisch ziekenhuis Maastricht | ||
Full Title: The glutamate/GABA balance as novel therapeutic target for psychotic and cognitive symptoms in 22q11.2 deletion syndrome | ||
Medical condition: 22q11.2 deletion syndrome | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: NL (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2014-000424-23 | Sponsor Protocol Number: 331-13-211 | Start Date*: 2014-10-31 |
Sponsor Name:Otsuka Pharmaceutical Development & Commercialization, Inc. | ||
Full Title: A 2-month, Observational, Rollover Trial to Evaluate the Safety of Subjects with Agitation Associated with Dementia of the Alzheimer?s Type who were Previously Treated with Brexpiprazole (OPC-34712... | ||
Medical condition: Agitation Associated with Dementia of the Alzheimer's Type | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: ES (Completed) DE (Completed) SI (Completed) FR (Completed) GB (Completed) HR (Completed) BG (Completed) | ||
Trial results: View results |
EudraCT Number: 2014-002513-27 | Sponsor Protocol Number: 200862 | Start Date*: 2014-11-19 | |||||||||||
Sponsor Name:GlaxoSmithKline Research & Development Ltd | |||||||||||||
Full Title: A randomised, double-blind, placebo-controlled, parallel-group, multi-centre 24-week study to evaluate the efficacy and safety of mepolizumab adjunctive therapy in subjects with severe eosinophilic... | |||||||||||||
Medical condition: Subjects with severe asthma | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) SK (Completed) BE (Completed) DE (Completed) CZ (Completed) GR (Completed) EE (Completed) ES (Completed) NL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2009-013157-15 | Sponsor Protocol Number: 1218.74 | Start Date*: 2010-10-14 | |||||||||||
Sponsor Name:SCS Boehringer Ingelheim Comm.V | |||||||||||||
Full Title: A multicentre, international, randomised, parallel group, double blind study to evaluate Cardiovascular safety of linagliptin versus glimepiride in patients with type 2 diabetes mellitus at high ca... | |||||||||||||
Medical condition: Patients with documented diagnosis of T2DM with insufficient glycaemic control and at high risk of CV events prior to informed consent can be enrolled in the study. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) FR (Completed) DE (Completed) PT (Completed) CZ (Completed) ES (Completed) IE (Completed) FI (Completed) SE (Completed) GB (Completed) SK (Completed) IT (Completed) GR (Completed) BG (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2014-003609-14 | Sponsor Protocol Number: ZLB07_001CR | Start Date*: 2015-01-05 |
Sponsor Name:CSL Behring | ||
Full Title: A Multicenter Follow-up Study of Long-term Safety, Tolerability, and Efficacy of Immune Globulin Subcutaneous (Human) IgPro20 in Subjects With Primary Immunodeficiency | ||
Medical condition: Primary Immune Deficiency | ||
Disease: | ||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | |
Trial protocol: Outside EU/EEA | ||
Trial results: View results |
EudraCT Number: 2005-005512-24 | Sponsor Protocol Number: CT EP 01 | Start Date*: 2006-04-27 |
Sponsor Name:EctoPharma Limited | ||
Full Title: A phase IIa clinical trial to demonstrate the proof of concept of an experimental pediculicide lotion for the treatment of head lice | ||
Medical condition: Head louse infection | ||
Disease: | ||
Population Age: Children, Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2014-003409-13 | Sponsor Protocol Number: IgPro20_3006 | Start Date*: 2015-01-05 |
Sponsor Name:CSL Behring | ||
Full Title: A Multicenter Study of Long-Term Clinical Outcomes of Immune Globulin Subcutaneous (Human) (SCIG) IgPro20 in Subjects with Primary Immunodeficiency | ||
Medical condition: Primary Immune Deficiency | ||
Disease: | ||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | |
Trial protocol: Outside EU/EEA | ||
Trial results: View results |
EudraCT Number: 2014-002425-35 | Sponsor Protocol Number: NL2014-002425-35/SpartacusBrindisi | Start Date*: 2015-07-20 |
Sponsor Name:National Poisons Information Center, University Medical Center Utrecht | ||
Full Title: A Single Centered, Prospective, Open-labeled, Pharmacokinetic Pilot Study of Tacrolimus Administration via Rectiole | ||
Medical condition: Heart and lung transplantation patients | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: NL (Prematurely Ended) | ||
Trial results: View results |
EudraCT Number: 2006-000179-13 | Sponsor Protocol Number: AG0/2006/001 | Start Date*: 2006-03-09 |
Sponsor Name:University Hospital Ghent | ||
Full Title: Validation of the methodology of serum creatinine measurement and the estimated glomular filtration ratio | ||
Medical condition: volunteers with different stage of renal disease or without renal disease | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: BE (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2005-004109-27 | Sponsor Protocol Number: 2.12.05 | Start Date*: 2006-03-24 |
Sponsor Name:Neuropsychiatric clinic | ||
Full Title: A double-blind, placebo-controlled multi-centre trial of memantine in patients with Parkinsons’ disease dementia or dementia with Lewy bodies | ||
Medical condition: Parkinsons disease (PD)and dementia with Lewy bodies (DLB) are both common disease of the elderly. The majority of patients who survive for more than 10 years with PD eventually develope dementia ... | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: SE (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2018-001846-32 | Sponsor Protocol Number: BUS2018-1 | Start Date*: 2018-09-18 |
Sponsor Name:VO Barnmedicin, Skånes University Hospital | ||
Full Title: Treatment of NF1-related plexiform neurofibroma with trametinib; a single arm, open-label trial with the goals of volumetric partial remission and pain relief | ||
Medical condition: NF1-related plexiform neurofibroma | ||
Disease: | ||
Population Age: Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | |
Trial protocol: SE (Completed) | ||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
